Professor Ian Gilbert
FMedSci FRSE FRSC
Biological Chemistry and Drug Discovery, School of Life Sciences
I am a medicinal chemist and my research interests are in the design and synthesis of potential drugs. The mainstay of my work is synthetic medicinal chemistry as part of the Drug Discovery Unit (DDU). Where possible we make extensive use of molecular modeling to guide our synthetic efforts. I have a particular interests in the following aspects of drug discovery:
Neglected diseases such as human African trypanosomiasis, leishmaniasis and malaria.
Chemical validation of drug targets, including novel targets for which there is little or no precedence for drug discovery.
Novel approaches to and paradigms for drug discovery.
Mode of action studies and target identification.
I am Head of Chemistry in the DDU. Our main focuses are on neglected diseases and novel drug targets. The neglected diseases we are tackling are malaria, tuberculosis and the kinetoplastid diseases. We use both target-based approaches and phenotypic approaches (whole parasite screening). We have had particular success in validating the enzyme N-myristoyltransferase as a drug target in human African trypanosomiasis, and in identifying and optimising phenotypic hits. In our novel targets area, we aim to validate novel areas of biology as potential drug targets.
A parasitic infection that affects millions of people around the world is to be targeted by a £2.5 million drug discovery programme at the Universities of Dundee, Aberystwyth and Cardiff.
Review of the Year 2021 took place virtually today with the former Interim Dean, Inke Näthke sharing the highlights of activity within the School from 2021
University of Dundee research to tackle some of the world’s deadliest diseases has been boosted by new funding from the Bill & Melinda Gates Foundation.
Design and synthesis of potential therapeutic agents
|Fellows of the Academy of Medical Sciences||2021|
|Fellows of the Royal Society of Edinburgh||2020|